October 2009
by Jeffrey Ventimiglia; Amir H. Kalali, MD; and Roger McIntyre, MD, FRCPC
Mr. Ventimiglia is an analyst in the Drug Safety and Medical Affairs Department, Quintiles, Inc., Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California; and Dr. McIntyre is Associate Professor of Psychiatry and Pharmacology, Head, Mood Disorders Psychopharmacology Unit, University of Toronto, Ontario, Canada.
Psychiatry (Edgemont) 2009;6(10):12–15
This is protected content.
Popularity: unranked [?]
Related posts
- Treatment of Schizoaffective Disorder
- Use of Benzodiazepines in the Treatment of Anxiety
- Current Management of Schizophrenia: Antipsychotic Monotherapy versus Combination Therapy
Posted in Trend Watch | No Comments »
